{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:55:02Z","timestamp":1790704502375,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00487","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:30:35Z","timestamp":1552609835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations"],"prefix":"10.3389","volume":"10","author":[{"given":"Eleni","family":"Palli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evrydiki","family":"Kravvariti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0961203309360541","article-title":"Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort","volume":"19","author":"Petri","year":"2010","journal-title":"Lupus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3389\/fimmu.2018.01181","article-title":"Antiphospholipid syndrome nephropathy: from pathogenesis to treatment","volume":"9","author":"Tektonidou","year":"2018","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11926-016-0566-z","article-title":"Emerging therapies in antiphospholipid syndrome","volume":"18","author":"Andrade","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","article-title":"Activation of the type I interferon pathway in primary Sjogren's syndrome","volume":"35","author":"Mavragani","year":"2010","journal-title":"J Autoimmun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1002\/art.23035","article-title":"Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus","volume":"56","author":"Lee","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e86069","DOI":"10.1371\/journal.pone.0086069","article-title":"IFNalpha serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients","volume":"9","author":"Rodriguez-Carrio","year":"2014","journal-title":"PLoS ONE"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1093\/rheumatology\/ket403","article-title":"Type I interferon blockade in systemic lupus erythematosus: where do we stand?","volume":"53","author":"Lauwerys","year":"2014","journal-title":"Rheumatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.gene.6364443","article-title":"Innate immune response gene expression profiles characterize primary antiphospholipid syndrome","volume":"9","author":"Bernales","year":"2008","journal-title":"Genes Immun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/annrheumdis-2016-209442","article-title":"Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome","volume":"76","author":"Grenn","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1136\/annrheumdis-2016-210485","article-title":"Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use","volume":"75","author":"van den Hoogen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/jth.13976","article-title":"Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH","volume":"16","author":"Devreese","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.clim.2013.02.013","article-title":"Anti-interferon alpha treatment in SLE","volume":"148","author":"Kirou","year":"2013","journal-title":"Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"93897","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/0961203316641772","article-title":"Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools","volume":"25","author":"Meroni","year":"2016","journal-title":"Lupus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3389\/fimmu.2016.00678","article-title":"NETopathies? Unraveling the dark side of old diseases through neutrophils","volume":"7","author":"Mitsios","year":"2016","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"key":"B28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0961203317724219","article-title":"APS ACTION","volume":"27","author":"Erkan","year":"2018","journal-title":"Lupus."},{"key":"B29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaut.2016.04.008","article-title":"Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome","volume":"75","author":"Bertolaccini","year":"2016","journal-title":"J Autoimmun."},{"key":"B30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb Haemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.autrev.2017.05.006","article-title":"on the behalf of the SNFMI and the European Forum on Antiphospholipid Antibodies","volume":"16","author":"Mekinian","year":"2017","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:30:37Z","timestamp":1552609837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2019.00487"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00487","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"article-number":"487"}}